These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 15923430)

  • 1. Specific TP53 and/or Ki-ras mutations as independent predictors of clinical outcome in sporadic colorectal adenocarcinomas: results of a 5-year Gruppo Oncologico dell'Italia Meridionale (GOIM) prospective study.
    Bazan V; Agnese V; Corsale S; Calò V; Valerio MR; Latteri MA; Vieni S; Grassi N; Cicero G; Dardanoni G; Tomasino RM; Colucci G; Gebbia N; Russo A;
    Ann Oncol; 2005 May; 16 Suppl 4():iv50-55. PubMed ID: 15923430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic and predictive factors in colorectal cancer: Kirsten Ras in CRC (RASCAL) and TP53CRC collaborative studies.
    Russo A; Bazan V; Agnese V; Rodolico V; Gebbia N
    Ann Oncol; 2005 May; 16 Suppl 4():iv44-49. PubMed ID: 15923428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular detection of TP53, Ki-Ras and p16INK4A promoter methylation in plasma of patients with colorectal cancer and its association with prognosis. Results of a 3-year GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective study.
    Bazan V; Bruno L; Augello C; Agnese V; Calò V; Corsale S; Gargano G; Terrasi M; Schirò V; Di Fede G; Adamo V; Intrivici C; Crosta A; Rinaldi G; Latteri F; Dardanoni G; Grassi N; Valerio MR; Colucci G; Macaluso M; Russo A;
    Ann Oncol; 2006 Jun; 17 Suppl 7():vii84-90. PubMed ID: 16760301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of K-ras and TP53 mutations in the role of adjuvant chemotherapy on survival in patients with Dukes C colon cancer.
    Bleeker WA; Hayes VM; Karrenbeld A; Hofstra RM; Verlind E; Hermans J; Poppema S; Buys CH; Plukker JT
    Dis Colon Rectum; 2001 Mar; 44(3):358-63. PubMed ID: 11289281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cetuximab plus FOLFOX-4 in untreated patients with advanced colorectal cancer: a Gruppo Oncologico dell'Italia Meridionale Multicenter phase II study.
    Colucci G; Giuliani F; Garufi C; Mattioli R; Manzione L; Russo A; Lopez M; Parrella P; Tommasi S; Copetti M; Daniele B; Pisconti S; Tuveri G; Silvestris N; Maiello E
    Oncology; 2010; 79(5-6):415-22. PubMed ID: 21474966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study.
    Kaczirek K; Ciuleanu TE; Vrbanec D; Marton E; Messinger D; Liegl-Atzwanger B; Wrba F; Knittelfelder R; Lindner E; Zielinski CC; Streubel B; Brodowicz T
    Clin Colorectal Cancer; 2015 Jun; 14(2):91-8. PubMed ID: 25666295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical impact of K-ras mutation in colorectal cancer patients treated with adjuvant FOLFOX.
    Chang MH; Lee IK; Si Y; Lee KS; Woo IS; Byun JH
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):317-23. PubMed ID: 20972872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p53 and Ki-ras as prognostic factors for Dukes' stage B colorectal cancer.
    Bouzourene H; Gervaz P; Cerottini JP; Benhattar J; Chaubert P; Saraga E; Pampallona S; Bosman FT; Givel JC
    Eur J Cancer; 2000 May; 36(8):1008-15. PubMed ID: 10885605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alterations in K-ras, APC and p53-multiple genetic pathway in colorectal cancer among Indians.
    Malhotra P; Anwar M; Nanda N; Kochhar R; Wig JD; Vaiphei K; Mahmood S
    Tumour Biol; 2013 Jun; 34(3):1901-11. PubMed ID: 23526092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of K-RAS and B-RAF mutations as biomarkers in metastatic colorectal cancer.
    Selcukbiricik F; Erdamar S; Ozkurt CU; Molinas Mandel N; Demirelli F; Ozguroglu M; Tural D; Buyukunal E; Serdengecti S
    J BUON; 2013; 18(1):116-23. PubMed ID: 23613396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a biomarker profile associated with resistance to neoadjuvant chemoradiation therapy in rectal cancer.
    Garcia-Aguilar J; Chen Z; Smith DD; Li W; Madoff RD; Cataldo P; Marcet J; Pastor C
    Ann Surg; 2011 Sep; 254(3):486-92; discussion 492-3. PubMed ID: 21865946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dukes B colorectal cancer: distinct genetic categories and clinical outcome based on proximal or distal tumor location.
    Gervaz P; Bouzourene H; Cerottini JP; Chaubert P; Benhattar J; Secic M; Wexner S; Givel JC; Belin B
    Dis Colon Rectum; 2001 Mar; 44(3):364-72; discussion 372-3. PubMed ID: 11289282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype.
    Bazan V; Migliavacca M; Zanna I; Tubiolo C; Grassi N; Latteri MA; La Farina M; Albanese I; Dardanoni G; Salerno S; Tomasino RM; Labianca R; Gebbia N; Russo A
    Ann Oncol; 2002 Sep; 13(9):1438-46. PubMed ID: 12196370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer.
    Van Cutsem E; Lenz HJ; Köhne CH; Heinemann V; Tejpar S; Melezínek I; Beier F; Stroh C; Rougier P; van Krieken JH; Ciardiello F
    J Clin Oncol; 2015 Mar; 33(7):692-700. PubMed ID: 25605843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implication of K-ras and p53 in colorectal cancer carcinogenesis in Tunisian population cohort.
    Ines C; Donia O; Rahma B; Ben Ammar A; Sameh A; Khalfallah T; Abdelmajid BH; Sabeh M; Saadia B
    Tumour Biol; 2014 Jul; 35(7):7163-75. PubMed ID: 24763823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
    Douillard JY; Oliner KS; Siena S; Tabernero J; Burkes R; Barugel M; Humblet Y; Bodoky G; Cunningham D; Jassem J; Rivera F; Kocákova I; Ruff P; Błasińska-Morawiec M; Šmakal M; Canon JL; Rother M; Williams R; Rong A; Wiezorek J; Sidhu R; Patterson SD
    N Engl J Med; 2013 Sep; 369(11):1023-34. PubMed ID: 24024839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TP53 mutations in colorectal cancer from Tunisia: relationships with site of tumor origin, microsatellite instability and KRAS mutations.
    Aissi S; Buisine MP; Zerimech F; Kourda N; Moussa A; Manai M; Porchet N
    Mol Biol Rep; 2014 Mar; 41(3):1807-13. PubMed ID: 24443225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of HPV with genetic and epigenetic alterations in colorectal adenocarcinoma from Indian population.
    Laskar RS; Talukdar FR; Choudhury JH; Singh SA; Kundu S; Dhar B; Mondal R; Ghosh SK
    Tumour Biol; 2015 Jun; 36(6):4661-70. PubMed ID: 25647260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment.
    Russo A; Bazan V; Iacopetta B; Kerr D; Soussi T; Gebbia N;
    J Clin Oncol; 2005 Oct; 23(30):7518-28. PubMed ID: 16172461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel K-ras mutation in colorectal cancer. A case report and literature review.
    Palmirotta R; Savonarola A; Formica V; Ludovici G; Del Monte G; Roselli M; Guadagni F
    Anticancer Res; 2009 Aug; 29(8):3369-74. PubMed ID: 19661358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.